| symbol |
AQXP |
|---|
| 会社名 | Aquinox Pharmaceuticals Inc （アクイノックス・ファ―マシュ―ティカルズ） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
医薬品
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Aquinox Pharmaceuticals Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme which is a regulator of a cellular signaling pathway in immune cells known as the phosphatidylinositol-4 5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate AQX-1125 is a small molecule activator of SHIP1 suitable for oral once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS) a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety anti-inflammatory potential and drug properties in multiple preclinical studies. アクイノックス・ファ―マシュ―ティカルズは、米国の製薬会社。癌や炎症性疾患の低分子治療薬の発見、開発に従事。同社の抗炎症製品候補はPI3K経路として知られている免疫細胞で重要な細胞シグナル伝達経路の重要な調節因子であるSHIP1をタ―ゲットとする。主要製品候補のAQX-1125は、SHIP1活性化剤で幅広い抗炎症活性を促す。 Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada.
|
|---|
| 本社所在地 | 450-887 Great Northern Way Vancouver British Columbia V5T 4T5 CAN |
|---|
| 代表者氏名 | David J. Main David J. Main |
|---|
| 代表者役職名 | Co-Founder President and Chief Executive Officer and Chairman of the Board |
|---|
| 電話番号 | +1 604-629-9223 |
|---|
| 設立年月日 | 39203 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 2014年 |
|---|
| 従業員数 | 51人 |
|---|
| url | www.aqxpharma.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/aqxp |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -40.72900 |
|---|
| 終値（lastsale） | 2.75 |
|---|
| 時価総額（marketcap） | 64727762 |
|---|
| 時価総額 | 時価総額（百万ドル） 63.08015 |
|---|
| 売上高 | 売上高（百万ドル） 25.00000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） -39.03285 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -42.10600 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aquinox Pharmaceuticals Inc revenues increased from $0K to $25M. Net loss decreased 47% to $11.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income increase of 29% to $624K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.94 to -$0.50. |
|---|
AQXP - アクイノックス・ファ―マシュ―ティカルズ （Aquinox Pharmaceuticals Inc.） アクイノックス・ファ―マシュ―ティカルズ